Trisodium citrate 4% - An alternative to heparin capping of haemodialysis catheters

Nephrology Dialysis Transplantation

Volumn 22, Issue 2, 2007, Pages 477-483

  Lok, Charmaine E ^a,b   Appleton, Debra ^a,b   Bhola, Cynthia ^a,b   Khoo, Brian ^a,b   Richardson, Robert M A ^a,b  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Citrate; Haemodialysis catheters; Heparin; TPA

Indexed keywords

CITRATE TRISODIUM; HEPARIN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; CENTRAL VENOUS CATHETER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIALYSIS CATHETER; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; DRUG USE; ECONOMIC EVALUATION; FEMALE; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VASCULAR ACCESS;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; CATHETERS, INDWELLING; CITRATES; COST-BENEFIT ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HEPARIN; HUMANS; INCIDENCE; MALE; MIDDLE AGED; ONTARIO; PROSPECTIVE STUDIES; RENAL REPLACEMENT THERAPY; VENOUS THROMBOSIS;

EID: 33846671513     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl570     Document Type: Article

References (36)

1. Bregman H, Hoover M. The double lumen subcalvian cannula - a unique concept in vascular access. Dial Transplant 1982; 12: 1065-1070
2. Foundation NK. NKF-K/DOQI Clinical practice guidelines for vascular access: Update 2000. Am J Kidney Dis 2001; 37 [Suppl 1]: S137-S181
3. Ethier JH, Lindsay RM, Barre PE, Kappel JE, Carlisle EJ, Common A. Clinical practice guidelines for vascular access. Canadian Society pf Nephrology. J Am Soc Nephrol 1999; 10 [Suppl 13]: S297-S305
4. Rayner HC, Besarab A, Brown WW, Disney A, Saito A, Pisoni RL. Vascular access results from the Dialysis Outcomes and Practice Patterns Study (DOPPS): Performance against Kidney Disease Outcomes Quality Initiative (K/DOQI) Clinical Practice Guidelines. Am J Kidney Dis 2004; 44 [5 Suppl 3]: 22-26
5. Vasular access incidence and prevalance: Data from a preliminary Canadian Organ Replacement Register (CORR) report presented at the Canadian Society of Nephrology Annual Meeting, Vascular Access Symposium,Calgary, Alberta. Unpublished 2004
6. Beathard GA. Catheter Thrombosis. Semin Dial 2001; 14: 441-445
7. Weijmer MC, van den Dorpel MA, Van de Ven PJ et al. Randomized, clinical trial comparison of trisodium citrate 30% and heparin as catheter-locking solution in haemodialysis patients. J Am Soc Nephrol 2005; 16: 2769-2777
8. Lee T, Barker J, Allon M. Tunneled catheters in haemodialysis patients: reasons and subsequent outcomes. Am J Kidney Dis 2005; 46: 501-508
9. Duncan N, Singh S, Amao M et al. A single centre randomised trial of sodium citrate versus heparin line locks for cufed central venous catheters (abstract). J Am Soc Nephrol 2005: 451A
10. Karaaslan H, Peyronnet P, Benevent D, Lagarde C, Rince M, Leroux-Robert C. Risk of heparin lock-related bleeding when using indwelling venous catheter in haemodialysis. Nephrol Dial Transplant 2001; 16: 2072-2074
11. Bauer E, Derfler K, Joukhadar C, Druml W. Citrate kinetics in patients receiving long-term haemodialysis therapy. Am J Kidney Dis 2005; 45: 903-907
12. Follea G, Laville M, Pozet N, Dechavanne M. Pharmacokinetic studies of standard heparin and low molecular weight heparin in patients with chronic renal failure. Haemostasis 1986; 16: 147-151
13. Ashouri O. Regional sodium citrate anticoagulation in patients with active bleeding undergoing haemodialysis. Uremia Ivest 1985-1986; 9: 45-51
14. Ashton DN, Mehta RL, Ward DM, McDonald BR, Aguilar MM. Recent advances in continuous renal replacement therapy: Citrate anticoagulated continuous arteriovenous haemodialysis. ANNA J 1991; 18: 263-267
15. Bayes B, Bonal J, Romero R. Sodium citrate for filling haemodialysis catheters. [see comment]. Nephrol Dial Transplant 1999; 14: 2532-2533
16. Stas KJ, Vanwalleghem J, De Moor B, Keuleers H. Trisodium citrate 30% vs. heparin 5% as catheter lock in the interdialytic period in twin- or double-lumen dialysis catheters for intermittent haemodialysis. [comment]. Nephrol Dial Transplant 2001; 16: 1521-1522
17. Duncan L, Heathcote J, Djurdjev O, Levin A. Screening for renal disease using serum creatinine: Who are we missing? Nephrol Dial Transplant 2001; 16: 1042-1046
18. Cardinal P, Allan J, Pham B, Hindmarsh T, Jones G, Delisle S. The effect of sodium citrate in arterial catheters on acid-base and electrolyte measurements. Crit Care Med 2000; 28: 1398-1392
19. Flanigan MJ, Von Brecht J, Freeman RM, Lim VS. Reducing the hemorrhagic complications of haemodialysis: A controlled comparison of low-dose heparin and citrate anticoagulation. Am Journal Kidney Dis 1987; 9: 147-153
20. Food and Drug Administration: FDA issues warning on triCitrasol dialysis catheter anticoagulant; April 2000.
21. Branson PK, McCoy RA, Phillips BA, Clifton GD. Efficacy of 1.4 percent sodium citrate in maintaining arterial catheter patency in patients in a medical ICU. Chest 1993; 103: 882-885
22. Michaud D, Komant T, Pfefferle P. Four percent trisodium citrate as an alternative anticoagulant for maintaining patency of central venous haemodialysis catheters: Case report and discussion. Am J Crit Care 2001; 10: 351-354
23. Buturovic J, Ponikvar R, Kandus A, Boh M, Klinkmann J, Ivanovich P. Filling haemodialysis catheters in the interdialytic period: Heparin versus citrate versus polygeline: A prospective randomized study. Artif Organs 1998; 22: 945
24. Hendrickx L, Kuypers D, Evenepoel P, Maes B, Messiaen T, Vanrenterghem Y. A comparative prospective study on the use of low concentrate citrate lock versus heparin lock in permanent dialysis catheters. Int J Artif Organs 2001; 24: 208-211
25. Plamondon I, Agharazii, E.A., Langlois, S., Desmeules, S. Randomized cross-over comparison of 4% citrate and heaprin for catheter lock of double lumen haemodialysis catheters (abstract). J Am Soc Nephrol 2005: 12A
26. Kalman PG, Pope M, Bhola C, Richardson R, Sniderman KW. A practical approach to vascular access for haemodialysis and predictors of success. J Vasc Surg 1999; 30: 727-733
27. Evenepoel P, Maes B, Vanwalleghem J, Kuypers D, Messiaen T, Vanrenterghem Y. Regional citrate anticoagulation for haemodialysis using a conventional calcium-containing dialysate. Am J Kidney Dis 2002; 39: 315-323
28. Ash SR, Mankus R.A, Sutton J.M. Concentrated sodium citrate (23%) for catheter lock. Haemodial Int 2000; 4: 22-31
29. Weijmer MC, Debets-Ossenkopp YJ, Van De Vondervoort FJ, ter Wee PM. Superior antimicrobial activity of trisodium citrate over heparin for catheter locking. Nephrol Dial Transplant 2002; 17: 2199-2195
30. Lok CE, Stanley KE, Hux JE, Richardson R, Tobe SW, Conly J. Haemodialysis infection prevention with polysporin ointment. J Am Soc Nephrol 2003; 14: 169-179
31. Levesque N, Girard L, Leger J, Dorval M. Stability of trisodium citrate 4.0% and 46.7% in polyvinyl chloride syringes. Can J Hosp Pharm 2001; 54: 264-268
32. Kutsogiannis DJ, Gibney RT, Stollery D, Gao J. Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney Int 2005; 67: 2361-2367
33. Polaschegg HD, Shah C. Overspill of catheter locking solution: Safety and efficacy aspects. ASAIO J 2003; 49: 713-715
34. Kramer L, Bauer E, Joukhadar C et al. Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients. Crit Care Med 2003; 31: 2450-2455
35. Polaschegg HD, Sodemann K. Risks related to catheter locking solutions containing concentrated citrate. Nephrol Dial Transplant 2003; 18: 2688-2690
36. McFarlane PA, Bayoumi AM. Acceptance and rejection: Cost-effectiveness and the working nephrologist. Kidney Int 2004; 66: 1735-1741